Contract award notice: Medication supply: Dolutegravir
50 mg, Abacavir 600 mg, Lamivudine 300 mg to the hcsc pharmacy service (spain-madrid: Various medicinal products)
The Ministry of Health and Social Services (MHSS) has introduced a new drug known as Dolutegravir
for patients on HIV treatment.
FLAIR (NCT02938520) is a phase III, randomised, open-label, multicentre, parallel-group, non-inferiority study designed to assess the antiviral activity and safety of a 2-drug regimen of intramuscular, long-acting, injectable cabotegravir and rilpivirine in virologically suppressed adults living with HIV, following 20 weeks of induction therapy with Triumeq (abacavir, dolutegravir
and lamivudine tablets).
ENPNewswire-July 31, 2019--ViiV Healthcare - Five years on, 3.9 million people in the developing world have access to HIV treatment dolutegravir
, thanks to access-oriented voluntary licensing agreements
De nouvelles donnees ont ete presentees concernant l'utilisation de l'antiretroviral dolutegravir
(DTG) chez les femmes enceintes et en age de procreer.
NOTE OF CAUTION The organisation says it is updating its HIV therapy guidelines to strengthen its recommendation for dolutegravir
(DTG) drug as the first-line treatment because of its efficacy, tolerability and a high genetic barrier to resistance.
TUESDAY, July 23, 2019 (HealthDay News) -- For HIV-infected women receiving dolutegravir
from the time of conception, 0.3 percent have offspring with neural-tube defects, representing a small but significant increase compared with other antiretroviral treatment (ART) exposures, according to a study published online July 22 in the New England Journal of Medicine.
The TANGO study was conducted to assess whether adults living with HIV-1 who had maintained viral suppression for at least six months on a tenofovir alafenamide fumarate, or TAF,-containing regimen of at least three drugs, were able to maintain similar rates of viral suppression after switching to the 2-drug regimen, or 2DR, of dolutegravir
plus lamivudine in a fixed dose combination, compared to continuing the TAF-containing regimen.
Dovato, a two-drug regimen of dolutegravir
and lamivudine, was developed by ViiV Healthcare.
Recent safety concerns regarding the newly introduced first-line HIV integrase inhibitor dolutegravir
(DTG) have brought necessary attention to the need for pharmacovigilance during pregnancy and breastfeeding.
Another teaching moment for the medical community came last year, when an HIV drug called dolutegravir
was flagged as potentially causing birth defects through a study that surveilled the use of the drug in Botswana.
Public health agency the US Food and Drug Administration announced Monday that it has authorised the marketing of Dovato (dolutegravir
and lamivudine) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.